Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Jun 20, 2019 10:23 AM IST | Source: PTI

Glenmark Pharma gets tentative nod from USFDA for acne treatment drug

Glenmark Pharmaceuticals, USA, has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1 per cent, the company said in a BSE filing.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Glenmark Pharmaceuticals on Thursday it has received tentative approval from the US health regulator for Clindamycin Phosphate Foam, used to treat acne. The approved product is a generic version of Mylan Pharmaceuticals' Evoclin Foam.

Glenmark Pharmaceuticals, USA, has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1 per cent, the company said in a BSE filing.

For the 12 months to April 2019, Evoclin Foam market achieved annual sales of approximately USD 17 million, Glenmark said, citing IQVIA sales data.

Close

The company's current portfolio consists of 156 products authorised for distribution at the US marketplace and 59 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA.

The company's stock was trading 0.21 per cent lower at Rs 508.50 apiece on BSE.
First Published on Jun 20, 2019 10:15 am
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant